scholarly journals Profiling of Inflammatory Proteins in Plasma of HIV-1-Infected Children Receiving Antiretroviral Therapy

Proteomes ◽  
2020 ◽  
Vol 8 (3) ◽  
pp. 24
Author(s):  
Mahlet Lemma ◽  
Stefan Petkov ◽  
Yonas Bekele ◽  
Beyene Petros ◽  
Rawleigh Howe ◽  
...  

Treatment of HIV-1-infected patients results in improved clinical and immunological conditions, but severe non-AIDS-related conditions still persist. Novel proteomic platforms have identified inflammatory proteins where abundance is dysregulated in adult treated patients, whereas limited data are available in treated HIV-1 infection of children. Using a proteomic plasma profiling approach comprising 92 inflammation-related molecules, we analyzed specimens from 43 vertically HIV-1-infected children receiving antiretroviral treatment (ART) and matched controls in Ethiopia. The infected children were analyzed as a group and separately, according to age of treatment initiation. Proteins displaying a significantly different abundance between groups were hierarchically clustered and presented in heat maps. Random forest analysis was performed to pin-point proteins discriminating between groups; five proteins (STAMBP, CD5, TFG-α, TRANCE, AXIN1) were the strongest prediction factors for treated HIV-1 infection. TRANCE was previously linked to reduced bone mass levels in HIV-1-infected children. CCL4 chemokine, ligand to HIV-1 co-receptor CCR5, was the most critical protein for successful classification between children who initiated ART at different time points. Our data provide evidence that a dysregulated expression of proteins linked to immunological abnormalities and bone metabolism can be found in HIV-1-infected children with prolonged exposure to ART.

AIDS ◽  
2011 ◽  
Vol 25 (12) ◽  
pp. 1461-1469 ◽  
Author(s):  
Gillian M. Hunt ◽  
Ashraf Coovadia ◽  
Elaine J. Abrams ◽  
Gayle Sherman ◽  
Tammy Meyers ◽  
...  

Aids Reviews ◽  
2017 ◽  
Vol 19 (4) ◽  
Author(s):  
Valentina Svicher ◽  
Giulia Marchetti ◽  
Adrianna Ammassari ◽  
Francesca Ceccherini-Silberstein ◽  
Loredana Sarmati ◽  
...  

2020 ◽  
Vol 18 (5) ◽  
pp. 373-380 ◽  
Author(s):  
SeyedAhmad SeyedAlinaghi ◽  
Maryam Ghadimi ◽  
Mahboubeh Hajiabdolbaghi ◽  
Mehrnaz Rasoolinejad ◽  
Ladan Abbasian ◽  
...  

Background: COVID-19 has spread globally with remarkable speed, and currently, there is limited data available exploring any aspect of the intersection between HIV and SARSCoV- 2 co-infection. Objective: To estimate the prevalence of clinical symptoms associated with COVID-19 among people living with HIV (PLWH) in Tehran, Iran. Design: Cross-sectional study. Methods: A total of 200 PLWH were recruited through the positive club via sampling, and completed the symptom-based questionnaire for COVID-19, which was delivered by trained peers. Results: Of 200 participants, respiratory symptoms, including cough, sputum, and shortness of breath, were the most prevalent among participants, but only one person developed symptoms collectively suggested COVID-19 and sought treatments. Conclusions: It appears that existing infection with HIV or receiving antiretroviral treatment (ART) might reduce the susceptibility to the infection with SARS-CoV-2 or decrease the severity of the infection acquired. Further research is needed to understand causal mechanisms.


2009 ◽  
Vol 51 (1) ◽  
pp. 105-106 ◽  
Author(s):  
Ingrid Eshun-Wilson ◽  
Helen Van der Plas ◽  
Hans W Prozesky ◽  
Michele D Zeier ◽  
Jean Nachega ◽  
...  

2006 ◽  
Vol 81 (1) ◽  
pp. 362-373 ◽  
Author(s):  
Jan Balzarini ◽  
Kristel Van Laethem ◽  
Dirk Daelemans ◽  
Sigrid Hatse ◽  
Antonella Bugatti ◽  
...  

ABSTRACT Pradimicin A (PRM-A), an antifungal nonpeptidic benzonaphtacenequinone antibiotic, is a low-molecular-weight (molecular weight, 838) carbohydrate binding agent (CBA) endowed with a selective inhibitory activity against human immunodeficiency virus (HIV). It invariably inhibits representative virus strains of a variety of HIV-1 clades with X4 and R5 tropisms at nontoxic concentrations. Time-of-addition studies revealed that PRM-A acts as a true virus entry inhibitor. PRM-A specifically interacts with HIV-1 gp120 and efficiently prevents virus transmission in cocultures of HUT-78/HIV-1 and Sup T1 cells. Upon prolonged exposure of HIV-1-infected CEM cell cultures, PRM-A drug pressure selects for mutant HIV-1 strains containing N-glycosylation site deletions in gp120 but not gp41. A relatively long exposure time to PRM-A is required before drug-resistant virus strains emerge. PRM-A has a high genetic barrier, since more than five N-glycosylation site deletions in gp120 are required to afford moderate drug resistance. Such mutated virus strains keep full sensitivity to the other known clinically used anti-HIV drugs. PRM-A represents the first prototype compound of a nonpeptidic CBA lead and, together with peptide-based lectins, belongs to a conceptually novel type of potential therapeutics for which drug pressure results in the selection of glycan deletions in the HIV gp120 envelope.


2009 ◽  
Vol 52 (4) ◽  
pp. 493-497 ◽  
Author(s):  
Judith M Haissman ◽  
Lasse S Vestergaard ◽  
Samuel Sembuche ◽  
Christian Erikstrup ◽  
Bruno Mmbando ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document